The short answer
TruPlus is an enhanced-design monofocal lens. Alcon describes a small extension of focus beyond its standard Clareon monofocal. That is a different aim from a trifocal lens, which distributes light between several viewing distances.
The FDA approved the TruPlus design in February 2026. But approval is not proof that it gives better computer vision than Eyhance, Aspire or RayOne EMV. In the open sources checked for this review on 11 October 2026, the key improvement figures were laboratory simulations; registered patient studies had no posted results.
What Alcon promises—and what the number means
The manufacturer describes its Opti-Balance design as preserving distance image quality while adding a little intermediate vision. One figure is approximately 3.5 extra letters of simulated acuity at 66 cm compared with a Clareon monofocal. The word simulated matters: this is not the average improvement observed in a clinical comparison of patients.
A model eye can show a useful optical difference. It cannot tell you how often people use glasses at their own desk, whether a dim restaurant menu is comfortable, or how dry eye and residual astigmatism affect the result. Low halo and glare claims on the product page also rely on optical testing; they are not a published percentage of symptom-free patients.
A modest claim is not a weakness. It may describe the intended compromise more honestly than a broad promise of freedom from glasses. The unanswered part is the size and consistency of the benefit in everyday life.
FDA approval is real; comparative superiority is a separate question
The FDA record is PMA P190018, supplement S047, approved on 19 February 2026. It identifies TruPlus and TruPlus Toric, including blue-light-filtering and UV-absorbing configurations, supplied separately or with the AutonoMe injector.
This is a design-change supplement, not a new public head-to-head trial report. The record checked here does not link a standalone Summary of Safety and Effectiveness Data, or SSED, for TruPlus. That does not mean no regulatory evidence was submitted. It means this public approval entry does not supply the patient comparison needed to verify a claim of superiority.
Ask for the exact model and the instructions approved in your country. A family name is not enough to establish which toric option, material variant or indication is being offered.
What the registered clinical studies can—and cannot—answer
| Study | What is available |
|---|---|
| NCT07502456: Alcon-sponsored | A single-group, unmasked study, with an estimated 122 participants and no posted results. It can describe outcomes after implantation, but has no other lens group to establish an advantage. |
| NCT07693205: Berkeley Eye Center | A randomized, participant- and examiner-masked comparison with a standard Clareon monofocal; estimated enrollment 180. Recruiting at its latest posted update, with completion estimated in July 2027 and no posted results. |
A registered plan is useful: it tells us which questions researchers intend to test. It is not a result. Estimated enrollment is not the number of people already followed. This is why an encouraging design and an established patient benefit must stay separate.
For the intermediate-vision promise, current public support is optical rather than a completed patient comparison in the sources checked. That is weaker evidence for your daily experience—not proof that the lens fails. See how to read clinical data for the difference between a laboratory result, an uncontrolled series and a randomized comparison.
TruPlus versus Eyhance, Aspire and a trifocal
Do not rank these lenses by unrelated charts. A result measured at 66 cm with glasses correcting the remaining prescription is not interchangeable with uncorrected vision at 80 cm. The intended focus in each eye also changes what the person can do without glasses.
Our Eyhance review and Aspire 141-eye study review examine their own evidence. They do not provide a direct TruPlus comparison. An absence of that comparison cannot establish either a winner or equivalence.
If you want reliable small-print reading without glasses, a slight extension beyond a monofocal is not the same proposition as a full-range or trifocal lens. Nor does the newer name remove the trade-offs that need discussing before surgery.
Bring the question back to your desk
Measure your normal screen distance and consider the lighting, font size and length of your working sessions. Reading a few letters once is not the same as comfortable work for several hours. See computer work and IOLs for a practical way to describe that need.
The operation plan matters alongside the lens: target refraction, astigmatism and eye health influence the final range. An online review cannot determine surgical suitability.
- Which exact TruPlus model would you use, and what focus would you target in each eye?
- What patient data support the result you expect at my screen distance—not just a laboratory curve?
- For which tasks should I still plan to wear glasses?
Our conclusion
TruPlus has a plausible, deliberately modest optical aim: retain distance performance and add some intermediate range. The approval is documented. The size of the everyday improvement, however, is not yet established by posted results of the patient comparisons reviewed here.
It belongs in a discussion of enhanced monofocals, not in a promise of complete spectacle independence. The next useful evidence would be a completed randomized comparison reporting intermediate vision, glasses use and patient experience—not another simulation alone.
Related owner video
Eyhance, Aspire and RayOne: pitfalls of enhanced monofocals (2025). Oleksii explains why testing distance and the remaining prescription matter. This is not a TruPlus review or new proof about TruPlus.
Sources and their limits
Sources checked 11 October 2026. Editorial review by IOL Adviser; not a medical prescription or a personal assessment of surgical suitability.
- Alcon: TruPlus product page and claim footnotes. Manufacturer source; optical simulations and data on file are not patient outcome measurements.
- FDA: P190018/S047. Primary regulatory record for the design approval, not evidence of comparative superiority.
- ClinicalTrials.gov: NCT07502456. Full registered design checked; no posted results at the review date.
- ClinicalTrials.gov: NCT07693205. Full registered design checked; randomized comparison planned, no posted results at the review date.
Educational information—not a diagnosis or medical prescription. An eye-care professional must assess your eyes and medical suitability before treatment or surgery.